The purpose of this clinical trial is to assess the safety and effectiveness of the rhBMP-2/ACS/INTER FIX™ device as compared to the autograft/INTER FIX™ device in patients with symptomatic degenerative disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
67
The INTER FIX™ device containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS).
The INTER FIX™ device containing autogenous bone taken from the patient's iliac crest.
Fusion
Fusion is defined as: 1. Evidence of bridging trabeculae. 2. No evidence of motion as defined by: a. No more than 3mm difference in translation on the lateral flexion/extension radiographs as determined by superimposing the two views, one upon the other. b. Less than 5° difference in angular motion between flexion and extension as seen on lateral flexion/extension radiographs. 3. No evidence of radiolucency surrounding greater than 50% of either device.
Time frame: 24 month
Pain/Disability Status
The self-administered Oswestry Low Back Pain Disability Questionnaire will be used. Success for each individual patient will be defined as pain/disability improvement postoperatively according to the following definition: Preoperative Score - Postoperative Score \>= 15
Time frame: 24 month
Neurological Status
Neurological status will be assessed preoperatively and postoperatively using a comprehensive neurological status scale.
Time frame: 24 month
Hip (Donor Site) Pain
Time frame: 24 month
Disc Height Measurement
Time frame: 24 month
General Health Status (SF-36)
Time frame: 24 month
Pain Status (back pain, leg pain)
Time frame: 24 month
Patient Satisfaction
Time frame: 24 month
Patient Global Perceived Effect
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 24 month